期刊文献+

乳腺癌新辅助化疗动脉灌注途径与静脉途径的对比 被引量:3

Comparative analysis of artery infusion chemotherapy and intravenous chemotherapy of neoadjuvant chemotherapy for breast cancer
下载PDF
导出
摘要 目的探讨乳腺癌新辅助化疗动脉灌注途径和静脉途径化疗的有效性。方法收集92例乳腺癌患者,均采用多柔比星为主的联合化疗方案,其中动脉组44例,行肿瘤区域动脉灌注化疗,必要时栓塞肿瘤供血动脉;静脉组48例,使用外周静脉全身化疗。观察两组患者的近期临床疗效及长期生存率。结果动脉组近期临床疗效明显优于静脉组(P<0.05),但长期生存期率两组间差异无统计学意义(P>0.05)。结论动脉灌注化疗可作为乳腺癌新辅助化疗的有效途径之一。 Objective To explore the efficacy of neoadjuvant chemotherapy for breast cancer by comparing the effects of artery infusion chemotherapy and intravenous chemotherapy. Methods A total of 92 patients with breast cancer were en- rolled, including 44 patients in artery infusion chemotherapy group and 48 patients in intravenous chemotherapy group, which all induced doxorubicin in combined chemotherapy. Chemotherapeutics were induced in tumor region by arterial infu- sion, and feeding arteries of tumor were embolized if necessary in artery infusion chemotherapy group. Intravenous chemo- therapy was done in intravenous chemotherapy group. The short-term curative effects and long-term survival rate of the two groups were compared. Results The short-term curative effect in artery infusion chemotherapy group was significantly better than that of intravenous chemotherapy group (P〈0.05), but there was no statistical significance difference of the long-term survival between the two groups (P〉0.05). Conclusion Arterial infusion chemotherapy could be one of the ef- fective methods of neoadjuvant chemotherapy for breast cancer.
出处 《中国介入影像与治疗学》 CSCD 北大核心 2015年第12期728-731,共4页 Chinese Journal of Interventional Imaging and Therapy
关键词 乳腺肿瘤 化学疗法 辅助 动脉灌注化疗 静脉化疗 Breast neoplasms Chemotherapy, adjuvant Artery infusion chemotherapy Intravenous chemotherapy
  • 相关文献

参考文献14

二级参考文献44

  • 1甘长清,苏新良,杨光伦,吴诚义,吴凯南.经尺动脉介入化疗治疗局部晚期乳腺癌27例临床分析[J].重庆医学,2005,34(3):407-408. 被引量:8
  • 2柳金彬.Ⅲ期乳腺癌应用动脉导管灌注的新辅助化疗[J].实用肿瘤学杂志,1995,9(3):53-54. 被引量:13
  • 3崔丰民,张英之,张炳绪,战人美.乳癌区域动脉化疗26例临床分析[J].中国实用外科杂志,1996,16(2):103-104. 被引量:5
  • 4Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy : findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer, 2002,95:681-695.
  • 5Sataloff DM, Mason BA, Prestipino A J, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. Am J Coil Surg, 1995,180: 297 -306.
  • 6Catherine A, lsabelle VP, Remi D, et al. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist, 2005, 10: 242-249.
  • 7Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg, 1998,176:502-509.
  • 8Gajdos C, Tarrier PI, Estabrook A, et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol, 2002,80:4-11.
  • 9Chen AM, Meric-Bemstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol, 2004,22:2303-2312.
  • 10Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy : prognostic significance and survival. Breast, 2003, 12: 320-327.

共引文献917

同被引文献27

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部